Across TCGA pan-cancer cohorts, MED15P9 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated MED15P9 data layer.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MED15P9 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MED15P9 expression acts as an unfavorable survival marker, although some lineages such as PAAD and ESCA show a favorable association.
LUAD, COAD, and KIRP are the cancer types where MED15P9 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.